Skepta and PUMA Launch Groundbreaking Collection 
Semaglutide's Benefits Beyond Weight Loss: New Insights from the SELECT Trial 
The 2023 Sir Paul Curran award for academic journalism goes to Barbara Sahakian 
Lapstone & Hammer Expands ASICS 'Dip Dye' Series with Beverage-Inspired Colorways 
McDonald’s Rolls Out $5 Meal Deals to Emphasize Affordability Amid Rising Costs 
From Burger King to McDonald’s: Fast-Food Prices Surge Dramatically in Recent Years 
McDonald's Faces Backlash Over $5 Meal Deal: Customers Call It 'Skimpy' 
Nike vs. Adidas: Anthony Edwards’ and Wembanyama’s Sneakers Soar in Popularity 
BYD Launches Shark Hybrid Pickup in Mexico, Eyes New Factory Amid US Tariff Hike 
McDonald's Philippines Launches 'Ride the Arches' for Cyclists 
Green industry yes, conservation no: a budget for people, not for nature 
Coca-Cola Launches Lens Platform to Offer Key Data for Retail and Foodservice 
Coca-Cola Launches Data-Driven Insights Platform for Retail and Foodservice Industries 
Burger King Introduces Mozzarella Fries: A New Spin on an Old Favorite 
Shein's Potential London IPO Could Revitalize LSE Amid Geopolitical Tensions 
SAN DIEGO, April 19, 2016 -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report first quarter 2016 financial results on Tuesday, May 3, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
Conference Call Information
| Date: | Tuesday, May 3, 2016 |
| Time: | 4:30 p.m. ET |
| Dial-in numbers: | +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International) |
| Confirmation code: | 92067921 |
| Live webcast: | www.retrophin.com in the "Events & Presentations" section of the "Investors" page |
A replay of the call will be available 7:30 p.m. ET, May 3, 2016 to 7:30 p.m. ET, May 10, 2016. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 92067921.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets, including RE-034, in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's marketed products, Chenodal®, Cholbam® and Thiola®.
Contact: Chris Cline, CFA Director, Investor Relations 646-564-3680 [email protected]
